Pancreatica News Abstracts Archive - US Oncology Reports Clinical Trial Results Point to Potential New Treatment Option for Metastatic Pancreatic Cancer

Pancreas Cancer News and Archives

For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer

US Oncology Reports Clinical Trial Results Point to Potential New Treatment Option for Metastatic Pancreatic Cancer

OCOLA, Florida, January 16, 2002

Data published by a Florida physician affiliated with US Oncology, Inc., in a January issue of the Journal of Clinical Oncology reveals that the oral chemotherapy Xeloda® (capecitabine), recently approved for the treatment of metastatic colorectal and breast cancer, provides significant clinical benefit response and tumor response for patients with previously untreated advanced or metastatic pancreatic cancer.

The data, from a Phase II trial involving 42 patients, with Dr. Thomas Cartwright, of Ocola (Fla.) Oncology and US Oncology, Inc., as the Principal Investigator, shows clinical benefit response of 24 percent and an overall tumor response rate of 9.5 percent for patients treated with Xeloda.

Last year, the Food and Drug Administration (FDA) approved Xeloda (capecitabine) in combination with Taxotere® (docetaxel) for the treatment of metastatic breast cancer after failure of anthracyline therapy. Xeloda also is indicated as first-line treatment of patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred, as well as for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.

"Identifying new therapy options to treat pancreatic cancer is critical as current options are very limited and success is generally poor," said Dr. Cartwright. "Patients respond differently to different therapies; therefore, physicians need multiple options to consider. Our research suggests that Xeloda deserves more consideration and advanced study in pancreatic cancer."

Currently, the only product approved by the FDA for the treatment of pancreatic cancer is Gemzar® (gemcitabine).

Results of Dr. Cartwright's Phase II study show that treatment with Xeloda provides a clinical benefit response of 24 percent and an overall tumor response rate of 9.5 percent (CI: 90 percent), with the median time to objective response of 85 days (range 47-91 days). Of the 41 patients with measurable disease, three had a partial response, for an objective response rate of 7.3%. One patient with assessable (nonmeasurable) disease showed improved residual disease, with a positive clinical benefit response. Thus there were a total of four responders among the 42 patients treated, for an overall response rate of 9.5 percent (90 percent CI). The median survival was 182 days (6 months) (95 percent CI, 85-274 days) and duration of response ranged from 208 -- 566 days. All patients (22 men and 20 women) were treated with Xeloda 1250mg/m2/BID days 1-14 followed by a one-week rest period.

Xeloda was generally well tolerated in this study. The most common treatment-related adverse events were hand-foot syndrome and nausea, each occurring in approximately 50 percent of patients. The majority of adverse events were grade 1 or 2. The predominant grade 3 toxicities were hand-foot syndrome (17 percent), diarrhea (12 percent), and nausea (10 percent). Two patients (5%) experienced grade 4 diarrhea. There was no other grade 4 toxicity and there were no toxicity-related deaths.

Xeloda is the first oral drug that is enzymatically converted into the cancer-fighting substance 5-FU. The enzyme thymidine phosphorylase (TP), is higher at the site of the tumor than surrounding normal tissue. This finding has not been adequately studied in the clinical setting.

Xeloda® is manufactured by Roche.

According to the American Cancer Society, more than 30,000 people will be diagnosed with pancreatic cancer in 2002, and more than 29,000 people will die from the disease.

US Oncology, Inc., headquartered in Houston, Texas, is the nation's premier cancer care services company. The Cancer Research Services division of US Oncology offers an integrated platform for conducting phase I-IV clinical trials for new and approved cancer therapies through US Oncology's network of community-based physician practices and cancer centers. The US Oncology network operates in 27 states with over 850 affiliated physicians in over 450 locations, including 77 integrated cancer centers.

Press Release
SOURCE: US Oncology, Inc.

Home | Links | In The News | Clinical Trials Database
About Us | FAQ | Research Resources

webmaster

©2000-2008 Pancreatica.org - All Rights Reserved
www.pancreatica.org

	Pancreas Cancer News and Archives
		For educational purposes only; not to be relied upon. Please read Pancreatica Disclaimer
	US Oncology Reports Clinical Trial Results Point to Potential New Treatment Option for Metastatic Pancreatic Cancer OCOLA, Florida, January 16, 2002 Data published by a Florida physician affiliated with US Oncology, Inc., in a January issue of the Journal of Clinical Oncology reveals that the oral chemotherapy Xeloda® (capecitabine), recently approved for the treatment of metastatic colorectal and breast cancer, provides significant clinical benefit response and tumor response for patients with previously untreated advanced or metastatic pancreatic cancer. The data, from a Phase II trial involving 42 patients, with Dr. Thomas Cartwright, of Ocola (Fla.) Oncology and US Oncology, Inc., as the Principal Investigator, shows clinical benefit response of 24 percent and an overall tumor response rate of 9.5 percent for patients treated with Xeloda. Last year, the Food and Drug Administration (FDA) approved Xeloda (capecitabine) in combination with Taxotere® (docetaxel) for the treatment of metastatic breast cancer after failure of anthracyline therapy. Xeloda also is indicated as first-line treatment of patients with metastatic colorectal cancer when treatment with fluoropyrimidine therapy alone is preferred, as well as for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated. "Identifying new therapy options to treat pancreatic cancer is critical as current options are very limited and success is generally poor," said Dr. Cartwright. "Patients respond differently to different therapies; therefore, physicians need multiple options to consider. Our research suggests that Xeloda deserves more consideration and advanced study in pancreatic cancer." Currently, the only product approved by the FDA for the treatment of pancreatic cancer is Gemzar® (gemcitabine). Results of Dr. Cartwright's Phase II study show that treatment with Xeloda provides a clinical benefit response of 24 percent and an overall tumor response rate of 9.5 percent (CI: 90 percent), with the median time to objective response of 85 days (range 47-91 days). Of the 41 patients with measurable disease, three had a partial response, for an objective response rate of 7.3%. One patient with assessable (nonmeasurable) disease showed improved residual disease, with a positive clinical benefit response. Thus there were a total of four responders among the 42 patients treated, for an overall response rate of 9.5 percent (90 percent CI). The median survival was 182 days (6 months) (95 percent CI, 85-274 days) and duration of response ranged from 208 -- 566 days. All patients (22 men and 20 women) were treated with Xeloda 1250mg/m2/BID days 1-14 followed by a one-week rest period. Xeloda was generally well tolerated in this study. The most common treatment-related adverse events were hand-foot syndrome and nausea, each occurring in approximately 50 percent of patients. The majority of adverse events were grade 1 or 2. The predominant grade 3 toxicities were hand-foot syndrome (17 percent), diarrhea (12 percent), and nausea (10 percent). Two patients (5%) experienced grade 4 diarrhea. There was no other grade 4 toxicity and there were no toxicity-related deaths. Xeloda is the first oral drug that is enzymatically converted into the cancer-fighting substance 5-FU. The enzyme thymidine phosphorylase (TP), is higher at the site of the tumor than surrounding normal tissue. This finding has not been adequately studied in the clinical setting. Xeloda® is manufactured by Roche. According to the American Cancer Society, more than 30,000 people will be diagnosed with pancreatic cancer in 2002, and more than 29,000 people will die from the disease. US Oncology, Inc., headquartered in Houston, Texas, is the nation's premier cancer care services company. The Cancer Research Services division of US Oncology offers an integrated platform for conducting phase I-IV clinical trials for new and approved cancer therapies through US Oncology's network of community-based physician practices and cancer centers. The US Oncology network operates in 27 states with over 850 affiliated physicians in over 450 locations, including 77 integrated cancer centers. Press Release SOURCE: US Oncology, Inc.

	Home \| Links \| In The News \| Clinical Trials Database About Us \| FAQ \| Research Resources

	webmaster

	©2000-2008 Pancreatica.org - All Rights Reserved www.pancreatica.org